focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Hi Bob, really disappointed with continuing walk down of sp. It's only small steps each time but it destroys positive sentiment. We have experienced guys running the show and although they will be working hard with limited resources the CE Mark was critical for progress, we now now have it and it seems incumbent upon board to give shareholders some commercial expectations or deals 're clinical application. In to this happens we are in the current situation. No Santa rally here!!
Hi Tobriand, final results suggest although no JV we continue to work with Quibim to develop product for this. Regards
Morning Bob and Botak. From a patient's perspective sad to see life threatening delays, provides a great opportunity for Texrad lung. Key moment.
Nearly 10% of shares volume this week. Someone sees value and its very unusual volumes. TR1 bought over 4% in one day, not a punt for �50k+
Thanks profit and tobriand. Just need to fill that void in company promotion and start to give us some commercial deals please. Early integration of Texrad lung with Alliance would help radiologists diagnosis, ease volume workload and benefit so many patients.
Unusually high volume for under performing small cap. Recent TR1 from significant Luxembourg resident. One to watch? Very under radar.
Investopedia- Intense price competition on both buyers and sellers lead to tight spreads. Been tight for 3 months and more and looks like dropped today for 250,000 buy. See what happens tomorrow.
Is correct, standard RNS for AGM. Answers to most of your questions are in the end of year final results. Already RNS'd.
Hi adrianz, final results included "we continue to work closely with Alliance on the future integration of Texrad lung". I take it as a done deal, no mention of possible or potential.
Morning Bob, sleet and very cold in carrot crunching north Norfolk today. Although we are fairly stagnant sp wise I am reassured to see quite significant buys in last week. Several over 500k and Jimbob might be right in his suggestion that price being moved around to accommodate buyer. Spoke to Mike Hayball this morning about tomorrow's AGM, not expecting many, room for 14 and no requirement to pre register. Last year's AGM lasted 7 minutes and they are often dull affairs. Will make a late decision 're attendance. I deduced from conversation that CE1 Mark does indeed allow commercialization and deals to be struck also technically some of the work done on Texrad lung can be used in rinse and repeat for future other clinical applications.It would be great to get a positive statement of intent tomorrow from the board. The best AIM communicators offer something enjoyable other the tea and biscuits!
Thanks again! Agree that issue might be Texrad Ltd but they are not listed and the market will react to what the listed holding company Feedback plc gives them. Interesting period and one which requires shareholder patience.
What are your thoughts on company executive infrastructure? Only 2 executive directors both of whom are excellent technically and scientifically but company appears to lack full time executive leadership for a public listed company? Does the company currently have the capacity to deliver timely commercial progress?
Thanks for your perspective. Am hoping to attend AGM Thursday and glean more, even if it's only body language of key personnel.
Fantastic comeback El, hope they turn the corner and get some of those boys fit again. Local derby, cracking atmosphere, the Bees are gutted!
Hi Bob, what are you happily invested in? Integrity is paramount for me in life and everything.
Hi El, Another view is current situation benefits no one and company, shareholders et al suffer. Seems to be a complete lack of transparency all round. Poor comms from board and uncertainty about major shareholders intentions.
Noted.
We eke out some miniscule daily rises and then lose it all in few hours. Market clearly not currently buying in to our offering and something has to change to reassure potential buyers and existing shareholders. Balaji and Mike's superb work on the technical side not being capitalized on. I sometimes feel I am doing the company's promotional work for them!
I agree with both of you Botak and Tobriand. This will only happen either with a mature self assessment by the current executive or an equally mature collaborative approach by existing major shareholders. TB,TC,MH and BG are the main players here with our new TR1 man. I hope the great technology gets the opportunity to fulfil its undoubted potential in the clinical sector.
Tobriand. I sense that Texture analysis algorithms are continually being developed and will potentially become more accurate and useful to clinicians. Stonechecker Ltd (kidney stones) discovered additional clinical benefits during development and testing of their Texrad licenced software including extracting additional information simply about kidney stone size, volume and position. The company claim this enhancement will make product more attractive commercially and "easier to sell". AI is moving and developing quickly and who knows where we will be in 2/3 years time. Balaji Ganesan and his peer group will have a better idea than the rest of us and your hypothesis is certainly exciting.